October 23, 2020
Not intended for U.S. and UK Media – Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)’s Kidney Week 2020
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
